Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) Assets Average (2020 - 2025)

Keros Therapeutics (KROS) has disclosed Assets Average for 5 consecutive years, with $540.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Assets Average changed N/A year-over-year to $540.4 million, compared with a TTM value of $540.4 million through Dec 2025, changed N/A, and an annual FY2025 reading of $477.0 million, down 3.25% over the prior year.
  • Assets Average was $540.4 million for Q4 2025 at Keros Therapeutics, down from $750.0 million in the prior quarter.
  • Across five years, Assets Average topped out at $750.0 million in Q3 2025 and bottomed at $236.7 million in Q3 2021.
  • Average Assets Average over 4 years is $350.8 million, with a median of $263.6 million recorded in 2021.
  • The sharpest move saw Assets Average skyrocketed 636.82% in 2021, then decreased 6.98% in 2022.
  • Year by year, Assets Average stood at $242.6 million in 2021, then increased by 15.28% to $279.7 million in 2022, then increased by 24.48% to $348.1 million in 2023, then skyrocketed by 55.23% to $540.4 million in 2025.
  • Business Quant data shows Assets Average for KROS at $540.4 million in Q4 2025, $750.0 million in Q3 2025, and $348.1 million in Q4 2023.